Results 11 to 20 of about 98,375,777 (262)

Administration of fusion cytokines induces tumor regression and systemic antitumor immunity

open access: yesMedComm, 2021
It is difficult to improve the curative effects of cancer immunotherapy on solid tumors. Cytokines, as powerful immune regulators, show potential in activating host antitumor immunity.
Jinyu Zhang, Xuan Zhao
doaj   +1 more source

Differential effects of age on chicken heterophil functional activation by recombinant chicken interleukin-2 [PDF]

open access: yes, 2002
Interleukin-2 (IL-2) exercises an array of biological effects on many cells including the functional activation of cells of the innate immune response.
Pete Kaiser   +5 more
core   +1 more source

In vivo manipulation of interleukin-2 expression by a retroviral tetracycline (tet)-regulated system [PDF]

open access: yes, 2006
We have used the tetracycline (tet)-regulated system as described previously to evaluate the applicability of controlled gene expression in cancer gene therapy. As a model gene, we used the human interleukin-2 (IL-2) gene, which has been placed under the
Wirth, Thomas   +4 more
core   +1 more source

Interleukin-18 [PDF]

open access: yes, 2003
Interleukin-18 (IL-18), a recently described member of the IL-1 cytokine superfamily, is now recognized as an important regulator of innate and acquired immune responses.
McInnes, I.B.   +2 more
core   +1 more source

Human Mesenchymal Stem Cells Overexpressing Interleukin 2 Can Suppress Proliferation of Neuroblastoma Cells in Co-Culture and Activate Mononuclear Cells In Vitro

open access: yesBioengineering, 2020
High-dose recombinant interleukin 2 (IL2) therapy has been shown to be successful in renal cell carcinoma and metastatic melanoma. However, systemic administration of high doses of IL2 can be toxic, causing capillary leakage syndrome and stimulating pro ...
Daria S. Chulpanova   +9 more
doaj   +1 more source

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies [PDF]

open access: yes, 2012
BACKGROUND: Persistent inflammation has been proposed to contribute to various stages in the pathogenesis of cardiovascular disease. Interleukin-6 receptor (IL6R) signalling propagates downstream inflammation cascades.
Thomas, GN   +489 more
core   +1 more source

Abscopal responses in patients with metastatic melanoma involving skin and subcutaneous tissues treated with intralesional IL2 plus BCG

open access: yesFrontiers in Oncology, 2023
Cutaneous melanoma is relatively common with increasing incidence and significant mortality. While the mainstay of therapy is surgical, patients with stage III and IV disease fare poorer than those with early-stage disease and often benefit from adjuvant
Dejan Vidovic   +3 more
doaj   +1 more source

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy

open access: yesMolecular Therapy: Oncolytics, 2017
Adoptive cell therapy holds much promise in the treatment of cancer but results in solid tumors have been modest. The notable exception is tumor-infiltrating lymphocyte (TIL) therapy of melanoma, but this approach only works with high-dose ...
Riikka Havunen   +12 more
doaj   +1 more source

Priming by recombinant chicken interleukin-2 induces selective expression of IL-8 and IL-18 mRNA in chicken heterophils during receptor-mediated phagocytosis of opsonized and nonopsonized Salmonella enterica serovar enteritidis [PDF]

open access: yes, 2003
Heterophils, the principal avian polymorphonuclear leukocytes (PMNs) equivalent to the mammalian neutrophil, function as professional phagocytes against bacterial infections, mediate acute inflammation, and respond to cytokine stimulation to aid in ...
Michael H Kogut   +5 more
core   +1 more source

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy

open access: yesFrontiers in Pediatrics, 2020
Patients with high-risk neuroblastoma treated with continuous long-term infusion of anti-GD2 antibody dinutuximab beta (DB) in combination with IL-2 show an acceptable safety profile. Here, we compared treatment tolerance with and without IL-2.
Filiz Cicek   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy